by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. In mid-2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. Research Use in the COVID-19 pandemic The UK National Health Service (NHS) is testing the use of apixaban in treating post-recovery COVID-19. References External links Bristol Myers Squibb Direct Xa inhibitors Delta-lactams Pfizer brands Phenol ethers 2-Piperidinones Pyrazolopyridines Wikipedia medicine articles ready to translate